Virax Biolabs may sell up to $2,070,060.20 of ordinary shares through Wainwright under its updated at-the-market program. Investors can compare that available capacity with approximately $3,658,152 of prior sales under the same agreement, while the supplement also details the public-float calculation supporting the limit.
Key Highlights
- The prior ordinary shares sold under the Original and Second Prospectus Supplements had an aggregate sales price of approximately $3,658,152.
- The public float was calculated at $8,421,181 using 1,324,085 ordinary shares held by non-affiliates.
- Virax Biolabs ordinary shares closed at $2.56 on Sep. 3.
Virax Biolabs Group Limited (NASDAQ: VRAX) may sell up to $2,070,060.20 of ordinary shares through H.C. Wainwright & Co. under an updated at-the-market arrangement.
$2.07M Ordinary-Share Capacity
The ordinary shares carry a Par Value of $0.025 per share. The arrangement with Wainwright is dated Jan. 22, 2024, and the updated prospectus supplement is dated Sep. 4, 2026. Virax Biolabs said the new amount reflects the maximum offering price permitted under the applicable registration limitation and its public float. The supplement states that further ordinary-share sales would require another prospectus supplement if additional capacity becomes available.
Public Float Calculation
Virax Biolabs’ public float was calculated at $8,421,181 using 1,324,085 ordinary shares held by non-affiliates and a $6.36 per-share price. The ordinary shares closed at $2.56 on Sep. 3, 2026.
FAQs
Q: How much can Virax Biolabs sell through its ATM offering?
A: Virax Biolabs may offer ordinary shares with an aggregate price of up to $2,070,060.20 through Wainwright under the updated ATM arrangement.
Q: What prior sales are excluded from the new VRAX capacity?
A: Those supplements are dated January 22, 2024, and September 30, 2024, respectively.
Q: How was Virax Biolabs’ public float calculated?
A: The filing calculated the public float at $8,421,181 from 1,324,085 ordinary shares held by non-affiliates. It used $6.36 per share, the highest Nasdaq closing price during the specified 60-day period.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.